Literature DB >> 1359221

The case for clinical trials of tamoxifen for prevention of breast cancer.

T J Powles1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359221     DOI: 10.1016/0140-6736(92)93162-g

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

Review 1.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

2.  Antioxidant benefits of tamoxifen therapy for breast cancer?

Authors:  H Wiseman; C Rice-Evans; B Halliwell
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

3.  Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen.

Authors:  J Lukac; Z Kusić; D Kordić; M Koncar; A Bolanca
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 4.  Gynecologic effects of tamoxifen: case reports and review of the literature.

Authors:  R M Caputo; L J Copeland
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1996

5.  Pathology of endometrium treated with tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

6.  Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.

Authors:  A Mahfoudi; E Roulet; S Dauvois; M G Parker; W Wahli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

7.  Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue.

Authors:  H Pujol; J Girault; P Rouanet; S Fournier; J Grenier; J Simony; J B Fourtillan; J L Pujol
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Species differences in the metabolic activation of tamoxifen into genotoxic derivatives: risk assessment in women.

Authors:  F De Matteis; I N White; L L Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

Review 9.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

10.  The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.

Authors:  T J Powles; A L Jones; S E Ashley; M E O'Brien; V A Tidy; J Treleavan; D Cosgrove; A G Nash; N Sacks; M Baum
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.